Combination treatment for advanced dermatofibrosarcoma protuberans
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (toripalimab and anlotinib) with standard chemotherapy for a rare type of skin cancer called dermatofibrosarcoma protuberans (DFSP) that has not responded to the usual treatment (imatinib) or cannot be treated with other options. The goal is to see if this combination can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of DFSP that is advanced, cannot be surgically removed, or has spread to other parts of the body.
- Your DFSP has either stopped responding to standard treatment with imatinib, or you have no other good treatment options.
- You are in generally good health (able to carry out daily activities) and your heart, liver, kidneys, and blood counts are within acceptable ranges.
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs—DRP-104 and durvalumab—to see if they can shrink or slow advanced fibrolamellar carcinoma, a rare liver cancer. It is for patients whose cancer has gotten worse even after immunotherapy treatment.
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
This trial tests two experimental drugs (pemigatinib and retifanlimab) for advanced dedifferentiated liposarcoma that has not responded to other treatments. It aims to see if this combination can shrink tumors or slow cancer growth.
This trial tests a new drug (LM-108) combined with an existing immunotherapy (toripalimab) for people with advanced cancers that have a specific genetic feature (MSI-H or dMMR). The goal is to see if this combination can help when previous immunotherapy hasn't worked.
This trial tests APG-115 together with a PD-1 immune therapy in people with advanced liposarcoma or other advanced solid tumors. It may help by blocking tumor growth through a mix of direct tumor targeting and immune system activation.
This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.
Hear when a new Dermatofibrosarcoma Protuberans (DFSP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.